Hyperhidrosis impairs quality of life (QOL) in hidradenitis suppurativa (HS) patients and may exacerbate HS. However, there is limited literature on whether hyperhidrosis treatments improve HS disease. To systematically review literature on efficacy and tolerability of hyperhidrosis treatments in HS patients. In May 2021, MEDLINE and EMBASE databases were systematically searched by two reviewers per PRISMA guidelines for articles on hyperhidrosis and HS. Sixteen articles met inclusion criteria (2 randomized controlled trials [RCTs], one case-control study, three cross-sectional studies, 10 case-studies/ series), encompassing 252 HS patients across studies. They examined botulinum toxin A (BTX-A) (n = 6) and B (BTX-B) (n = 1), suction-curettage (n = 1), diode laser (n = 1), and microwave-based energy device (MED) (n = 3). Overall, BTX treatments improve HS severity, QOL, hyperhidrosis, and were well-tolerated. Suction-curettage did not improve disease. One HS patient tolerated diode laser well, with improvement in sweating and HS. One RCT studying MED was discontinued due to adverse events. Two studies reported MED-induced HS. BTX was overall helpful in HS patients, including in patients without concomitant hyperhidrosis. However, more prospective studies are needed to examine its utility in HS. There is potential harm of MEDs in HS. Most studies examining hyperhidrosis treatments in HS patients are low level of evidence. Larger RCTs should examine the efficacy and tolerability of hyperhidrosis treatments in HS.

No abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory often recalcitrant to treatment. There is a lack of an updated systematic data review for infliximab use in HS. We conducted a systematic review and meta-analysis of literature on infliximab in HS. This study was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and was pre-registered on PROSPERO (CRD42021283596). In 9/2021, MEDLINE and EMBASE were systematically searched for articles on infliximab in HS. Non-English, duplicate, and studies with <5 HS patients were excluded. Study quality was assessed utilizing Cochrane Risk of

BackgroundContact dermatitis (CD) causes significant impact on patient quality of life. It is the most common occupational skin disease, accounting for more than US $1 billion of medical costs. Patch testing (PT) is the criterion standard for diagnosis of allergic CD. Patients are increasingly using the Internet to obtain health information; however, the readability, quality, and timeliness of online health resources for CD and PT are unknown.ObjectiveThe objective was to determine the readability, quality, and timeliness of the most frequently accessed patient online health resources for CD and PT.MethodsA Google search was performed on March 20, 2021, using the terms “contact dermatitis,” “contact eczema,” “patch testing,” and “patch test.” Websites were evaluated using several well-validated tools/criteria.ResultsContact dermatitis and PT websites had only 2 of the 48 websites combined that met the recommended sixth-grade reading level for patients, with the majority characterized as “very poor” to “fair” quality. There was no correlation found between quality and readability of the CD and PT websites.ConclusionsThere is a need for improvement of online CD and PT health resources. Dermatologists should take the lead to vet websites and enhance online resources to improve patient care.

No abstract

At all times, please follow your tailored BASELINE treatment plan: Wash HS affected areas with [ ] wash daily. Apply __ __ time s daily to [armpits | around the breast |tummy folds | groin ]. Take ________ _ by mouth ___ _ time s daily Take .

No abstract

No abstract